Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Argenx
Company

Argenx

Tracked across 1 events · 6 articles · First seen May 08, 2026 · Last active May 11, 2026

Sentiment
75
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 75
Tech
FDA Expands VYVGART, VYVGART Hytrulo Label
The United States — Food and Drug Administration has approved a label expansion for Argenx's drugs, Efgartigimod alfa/hyaluronidase and Efgartigimod alfa/hyaluronidase, to include all adult patients living with generalized myasthenia gravis (gMG), regardless of serotype.…
Impact: Argenx received United States — Food and Drug Administration approval for a label expansion of its drugs Efgartigimod alfa/hyaluronidase and Efgartigimod alfa/hyaluronidase, allowing them to be used for all adult patients with generalized myasthenia gravis (gMG). This expands the market for Argenx's key products.
May 08, 2026 · 6 articles
Key Actions (1)
100 United States — Food and Drug Administration approved label expansion ArgenxFDA Expands VYVGART,...
NEWSDESK
Track Argenx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.